Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.79 USD | +2.94% | -8.61% | -70.00% |
Mar. 25 | HC Wainwright Initiates Genprex With Buy Rating, $10 Price Target | MT |
Mar. 22 | Genprex Closes $6.5 Million Registered Direct Offering of Shares, Accompanying Warrants | MT |
Financials (USD)
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 4.03M |
---|---|---|---|---|---|
Net income 2023 * | -32M | Net income 2024 * | -34M | EV / Sales 2023 * | - |
Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-
| Employees | 31 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 76.93% |
1 day | +2.40% | ||
1 week | -8.61% | ||
Current month | -35.81% | ||
1 month | -33.81% | ||
3 months | -70.00% | ||
6 months | -81.85% | ||
Current year | -70.00% |
Managers | Title | Age | Since |
---|---|---|---|
J. Varner
CEO | Chief Executive Officer | 67 | 09-03-31 |
Ryan Confer
DFI | Director of Finance/CFO | 42 | 09-03-31 |
Kate Combs
CTO | Chief Tech/Sci/R&D Officer | - | 21-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Brent Longnecker
BRD | Director/Board Member | 67 | 20-03-17 |
J. Varner
CEO | Chief Executive Officer | 67 | 09-03-31 |
Director/Board Member | 51 | 20-03-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 2.79 | +2.94% | 5 507 |
24-03-27 | 2.71 | -1.09% | 50,445 |
24-03-26 | 2.74 | -8.67% | 57,381 |
24-03-25 | 3 | -1.96% | 76,447 |
24-03-22 | 3.06 | +1.32% | 25,885 |
Delayed Quote Nasdaq, March 28, 2024 at 12:05 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-70.00% | 4.03M | |
+3.25% | 108B | |
+10.05% | 104B | |
+6.40% | 23.66B | |
-11.62% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-12.97% | 16.19B | |
+4.64% | 13.72B | |
+34.86% | 12.22B |